MicroTransponder was founded in Dallas, TX in 2007 when it licensed technology developed at University of Texas in Dallas (UTD) by Larry Cauller, who heads the cortical connections lab. The first wireless transponder was developed under a DARPA Revolutionizing Prosthetics grant to create a bi-directional neural interface for a prosthetic hand.
Northstar was founded in 1999 as Vertis Neuroscience headquartered in Seattle, WA, and the original goal was to develop electrical stimulation for chronic back pain. In 2003, under its new name, Northstar Neuroscience, then developed the Renova cortical stimulation system to deliver targeted electrical stimulation to the brain cortex as a treatment for stroke-related upper extremity.
Intrapace was founded in Mountain View, CA by Mir Imran in 2001 to develop an implantable system for the treatment of obesity. Once implanted and activated, the Abiliti system is designed to detect when a person consumes food or drink. When food or drink is detected, the system delivers a series of low-energy electrical impulses to the
Transneuronix, Inc. was founded in 1995 and was based in Mount Arlington, New Jersey. It was acquired by Medtronic in 2005. Before its acqusition by Medtronic, Transneuronix developed the Transcend, an implantable gastric stimulator device for the treatment of obesity by electrical stimulation of the stomach. Later, Medtronic developed the Transcend II IPG.
EnteroMedics Inc. was founded in St. Paul, MN in 2002 to develop a platform for vagus-nerve stimulation, primarily for obesity management. In March 2011 EnteroMedics received the CE Mark for its second-generation system – the Maestro RC. The EnteroMedics Maestro RC device delivers VBLOC® vagal blocking therapy to through laparoscopically implanted leads to intermittently block the vagus nerves using
Transoma was the name that Data Sciences International of St Paul, MN adopted in 2003 when it re-fucused its animal telemetry implant business to develop an implantable wireless system to capture electrocardiogram data for diagnosing human cardiac arrhythmias, as well as to monitor the electrical activity of the heart and transmit data from the patient’s home
In June 2011, Israeli neuromodulation systems developer BioControl Medical spun-off CerebralRx to market its FitNeS vagus nerve stimulation system for the treatment of refractory epilepsy. The FitNes system employs platform technology developed for the CardioFit® system for treating congestive heart failure (HF). CerebralRx spun out of BioControl Medical to expand the use of this technology outside of cardiology for the
Enopace Biomedical Ltd. was founded in 2008 by Yossi Gross in Caesarea, Israel. Very scant details are available besides that it is developing a neuromodulation system to treat patients with congestive heart failure. According to the company, its technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload. From Enopace’s patent